HVTN 111
Status:Completed
Phase:I
Principal Investigator(s):
Objective:The study tests 2 experimental HIV vaccines in different combinations, to see if these combinations result in different immune responses in the body. (The immune system helps a person fight infections). It also tests an injection device without needles that uses pressurized air to inject the vaccine, to see if this can improve the immune responses.
Last updated March 24, 2021
Prevention Option(s):HIV Vaccine
Study Design:Double-blind, Randomized
Arms and Assigned Interventions
Description
Mode of Delivery
ARMsExperimental
Official Code:
NCT02997969
Trial Sponsors:
BMGF, DAIDS, GSK, HVTN, IPPOX
Start Date
End Date
May 31, 2016
July 11, 2018
Enrollment:132
Age range:
18 Years ↔
40 Years
Population:Cisgender Men, Cisgender Women